← Leaderboards
Philip Peter Strandwitz
Holobiome, Inc.
$1,838,677
Attributed
$3,377,753
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2019–21$2.5M$1.9M$1.3M$625K$0
'19
'20
'21
Funding mix
By agency
NIH$3,377,753 · 3
By mechanism
R44$1,631,737 · 1
R34$1,446,416 · 1
R43$299,600 · 1
Top collaborators
- Jack Anthony Gilbert4 shared
Others in their field
Other Emerging Leaders on “Animals”
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Ted Ross · University Of Georgia$70,992,558
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,986,959
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$49,241,299
Research focus
AnimalsOralSafetyToxinGrowthGastrointestinal Tract StructureGut MicrobiomeProbioticsGut BacteriaStemImmuneSourceIn VitroFecesDoseBacteriaMicrobiomeAntibiotic SusceptibilityIn VivoIntervention StudiesIntestinesIrritable Bowel SyndromeGerm-FreeGenome
Grant awards (5)
Profiling the human gut microbiome for potential analgesic bacterial therapies$1,446,416
R34 · FY2021 · NS · contact PI
Development of therapeutic GABA-producing bacteria$667,602
R44 · FY2021 · DK · contact PI
Development of a therapeutic bacterial consortium for constipation$299,600
R43 · FY2021 · DK · contact PI
Development of therapeutic GABA-producing bacteria$664,418
R44 · FY2020 · DK · contact PI
Development of therapeutic GABA-producing bacteria$299,717
R44 · FY2019 · DK · contact PI